Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, Garofano RF, Stoopler MB, Cheng SK, White A, Lanuti M, D'Ovidio F, Bacchetta M, Sonett JR, Saqi A, Rizvi NA. Shu CA, et al. Lancet Oncol. 2020 Jun;21(6):786-795. doi: 10.1016/S1470-2045(20)30140-6. Epub 2020 May 7. Lancet Oncol. 2020. PMID: 32386568 Clinical Trial.
Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).
Pike LRG, Miao E, Boe LA, Patil T, Imber BS, Myall NJ, Pollom EL, Hui C, Qu V, Langston J, Chiang V, Grant M, Goldberg SB, Palmer JD, Prasad RN, Wang TJC, Lee A, Shu CA, Chen LN, Thomas NJ, Braunstein SE, Kavanagh BD, Camidge DR, Rusthoven CG. Pike LRG, et al. Among authors: shu ca. J Clin Oncol. 2024 Oct 20;42(30):3606-3617. doi: 10.1200/JCO.23.02668. Epub 2024 Jul 24. J Clin Oncol. 2024. PMID: 39047224
Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings.
Henick BS, Koch PD, Gainor JF, Awad MM, Chiuzan C, Izard S, Georgis Y, Mallick S, Garofano RF, Wong CV, Saqi A, Grindheim J, Schulze K, Sonett JR, Rizvi NA, Izar B, Taylor AM, Shu CA. Henick BS, et al. Among authors: shu ca. J Immunother Cancer. 2024 Dec 25;12(12):e009301. doi: 10.1136/jitc-2024-009301. J Immunother Cancer. 2024. PMID: 39721753 Free article. Clinical Trial.
PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Heymann JJ, Bulman WA, Swinarski D, Pagan CA, Crapanzano JP, Haghighi M, Fazlollahi L, Stoopler MB, Sonett JR, Sacher AG, Shu CA, Rizvi NA, Saqi A. Heymann JJ, et al. Among authors: shu ca. Cancer Cytopathol. 2017 Dec;125(12):896-907. doi: 10.1002/cncy.21937. Epub 2017 Oct 12. Cancer Cytopathol. 2017. PMID: 29024471 Free article.
Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer.
Biswas AK, Han S, Tai Y, Ma W, Coker C, Quinn SA, Shakri AR, Zhong TJ, Scholze H, Lagos GG, Mela A, Manova-Todorova K, de Stanchina E, Ferrando AA, Mendelsohn C, Canoll P, Yu HA, Paik PK, Saqi A, Shu CA, Kris MG, Massague J, Acharyya S. Biswas AK, et al. Among authors: shu ca. Cancer Discov. 2022 Apr 1;12(4):1002-1021. doi: 10.1158/2159-8290.CD-21-0910. Cancer Discov. 2022. PMID: 35078784 Free PMC article.
48 results